Carta PAYBACK di Mondadori
Su Mondadori Store, con la tua carta PAYBACK ti premi ad ogni acquisto.
In a groundbreaking development, a beacon of hope emerges for those battling pancreatic cancer. Following a decade-long hiatus, the FDA has granted approval to a revolutionary drug regimen, heralding a new dawn in the fight against metastatic pancreatic adenocarcinoma (mPDAC). Onivyde, an injectable medication crafted by Ipsen, takes center stage, offering a lifeline alongside oxaliplatin, fluorouracil, and leucovorin. As patients grapple with an aggressive adversary boasting a mere eight to eleven-month life expectancy, this milestone stands as a testament to resilience and progress. Backed by a rigorous trial encompassing 770 chemotherapy-naïve individuals, the regimen showcased unprecedented efficacy, elevating survival rates and response rates to unprecedented heights. Amidst the backdrop of adversity, this approval not only marks a triumph over disease but also signifies a beacon of hope for countless individuals embarking on the arduous journey towards healing.
Scrivi una recensione per "Onivyde"
Torna in cima
Leggi un estratto
dai un voto
